GoodRx (GDRX) Insider Trevor Bezdek Buys 73,434 Shares

Multiple Insiders Expand Stakes in GoodRx Holdings, Inc.

GoodRx Holdings, Inc. saw a coordinated round of insider transactions on June 16, 2026, when Trevor Bezdek and several colleagues each acquired 73,434 shares of the company. This group purchase included filings from Agnes Rey-Giraud, Scott Wagner, Ronald Bruehlman, Kelly Kennedy, and Hirsch Douglas Joseph, all picking up the exact same block of shares on the same date. These transactions add to a series of insider disclosures for the healthcare information provider as leadership continues to build out personal equity stakes.

Stock Trades Near Key Moving Averages

At the time of the June transactions, shares of GoodRx changed hands at $2.61. The equity moves within a 52-week range spanning from a low of $1.77 to a high of $5.81. Market participants tracking technical levels note that the price hovers near its 200-day moving average of $2.73, while trading below its 50-day moving average of $3.37. The company holds a market capitalization of roughly $1.16 billion.

Analysts Set New Price Targets

Wall Street firms recently updated their views on the stock, bringing fresh price targets and ratings into focus. On August 21, 2026, Barclays maintained an Underweight rating and adjusted its target to $4.00 from $3.00. Earlier in the month, on August 13, 2026, UBS kept a Neutral rating while lifting its target to $3.75 from $2.50. Citigroup maintained a buy rating on August 11, 2026, setting a target of $5.00, matching the target set by TD Cowen on the same day. Additionally, Wells Fargo kept an Overweight rating on August 7, 2026, raising its target to $5.00 from $3.50. Across 13 analyst opinions, the stock carries a mean price target of $4.03.

Inside the Digital Health Platform

GoodRx Holdings, Inc. operates a digital platform that helps consumers compare prices and save on prescription drugs in the United States. The enterprise offers curated pricing, subscription programs, telehealth services via GoodRx Care, and solutions for pet medications. By connecting patients with transparent pricing and pharmacy benefit tools, the company bridges gaps between consumers and traditional retail pharmacies.

Looking Ahead to Fall Earnings

Investors are keeping an eye on the company's financial calendar, with the next round of earnings results scheduled for release on November 3, 2026. These updates will provide further visibility into revenue trends, net margins, and overall platform growth following these insider purchases.